Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 - a review

Christine M Akamine; Hana M El Sahly

doi:10.1016/j.trsl.2021.12.007

Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 - a review

Transl Res. 2022 Apr:242:1-19. doi: 10.1016/j.trsl.2021.12.007. Epub 2021 Dec 23.

Authors

Christine M Akamine¹, Hana M El Sahly²

Affiliations

¹ Baylor College of Medicine, One Baylor Plaza, Houston, Texas. Electronic address: akamine@bcm.edu.
² Baylor College of Medicine, One Baylor Plaza, Houston, Texas.

Abstract

The mRNA therapeutics have been studied since the 1970s and the currently available mRNA vaccines against COVID-19 are the culmination of decades of scientific research. The mRNA vaccines BNT162b2 and mRNA-1273 have played a key role in our global response to the COVID-19 pandemic as they have demonstrated significant advantages over conventional vaccines and have proven to be highly effective against COVID-19 associated hospitalization and severe illness in large clinical trials and studies using real-world data.

Publication types

Review

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Pandemics / prevention & control
RNA, Messenger
SARS-CoV-2
Vaccines*

Substances

COVID-19 Vaccines
RNA, Messenger
Vaccines
BNT162 Vaccine